Belite Bio (BLTE) Company presentation summary

Mission and leadership

• Focused on early intervention with an oral treatment for macular degeneration, aiming to address unmet needs in retinal diseases.

• Leadership team has extensive experience in biotech, ophthalmology, drug development, and capital markets.

Pipeline and market opportunity

• Lead candidate tinlarebant targets Stargardt disease (STGD1) and geographic atrophy (GA), both with significant unmet needs and no FDA-approved oral treatments.

• Tinlarebant has received multiple regulatory designations, including Breakthrough Therapy and Orphan Drug status in several regions.

• The global AMD patient population is projected to grow from 196M in 2020 to 288M by 2040.

Mechanism of action and disease rationale

• Tinlarebant is a once-daily oral tablet that binds serum RBP4 to reduce retinol delivery to the eye, aiming to slow toxic byproduct formation implicated in STGD1 and GA.

• Both STGD1 and GA share a pathophysiology involving bisretinoid accumulation and retinal cell death, leading to vision loss.